| - 1                             |  |  |                  |
|---------------------------------|--|--|------------------|
| 1<br>2<br>3<br>4<br>5<br>6<br>7 | Luke L. Dauchot (SBN 229829) luke.dauchot@kirkland.com Alexander F. MacKinnon (SBN 146883) alexander.mackinnon@kirkland.com Nimalka R. Wickramasekera (SBN 268518) nimalka.wickramasekera@kirkland.com Kirkland & Ellis LLP 333 South Hope Street Los Angeles, California 90071 Telephone: (213) 680-8400 Facsimile: (213) 680-8500  Attorneys for Plaintiffs/Counterclaim | Todd G. Miller (SBN 163200) miller@fr.com Michael A. Amon (SBN 226221) amon@fr.com Fish & Richardson P.C. 12390 El Camino Real San Diego, California 92130 Phone: 858-678-5070/Fax: 858-678 Frank E. Scherkenbach (SBN 14254) scherkenbach@fr.com Fish & Richardson P.C. One Marina Park Drive |                  |
| 8                               | Defendants   | Boston, Massachusetts 02210-1878<br>Phone: 617-542-5070/Fax: 617-542   |                  |
| 9                               |  | Keeley I. Vega (SBN 259928)  |                  |
| 10                              |  | kvega@fr.com<br>Neil A. Warren (SBN 272770)<br>warren@fr.com   |                  |
| 11                              |  | Fish & Richardson P.C. 500 Arguello St., Ste. 500  |                  |
| 12                              |  | Redwood City, California 94063<br>Telephone: 650-839-5070/Fax: 650   | 920 5071         |
| 13                              |  | •  |                  |
| 14                              |  | Attorneys for Defendant/Countercla   | aimant           |
| 15                              | UNITED STA   | TES DISTRICT COURT   |                  |
| 16                              | SOUTHERN DIS   | TRICT OF CALIFORNIA  |                  |
| 17<br>18                        | WARSAW ORTHOPEDIC, INC.; MEDTRO<br>SOFAMOR DANEK U.S.A., INC.; MEDTR<br>PUERTO RICO OPERATIONS CO.; and  | NIC ) CASE NO. 3:12-cv-0273:<br>ONIC )<br>JOINT DISCOVERY P  | , ,              |
| 19                              | OSTEOTECH, INC.,   | ) PURSUANT TO FED. I   | R. CIV. P. 26(f) |
| 20                              | Plaintiffs,  | )  |                  |
| 21                              | VS.  | ) Date: February 21, 2013<br>) Time: 9:30 a.m.   |                  |
|                                 | NUVASIVE, INC.,  | ) Location: Hon. Dembin's  |                  |
| 22  <br>23                      | D. C. 1  | ) Judge: Hon. Mitchell D.  | Demoin           |
| 23                              | Defendant.   | \(\)   |                  |
| ,                               |  |  |                  |
| 24                              | AND RELATED COUNTERCLAIMS  |  |                  |
| 25                              |  |  |                  |
| 25<br>26                        |  |  |                  |
| 25                              |  |  |                  |



Plaintiffs Warsaw Orthopedic, Inc.; Medtronic Sofamor Danek U.S.A., Inc.; Medtronic Puerto Rico Operations Co.; and Osteotech, Inc. (collectively "Plaintiffs") and defendant NuVasive, Inc. ("NuVasive") hereby jointly submit the following discovery plan for the above-captioned matter pursuant to Fed. R. Civ. P. 26(f), Patent Local Rule 2.1, and Chamber Rule IV.B. As required by Rule 26(f)(1), the parties have met and conferred in an effort to reach agreement on this report. A short explanatory statement from each party is included on matters where the parties differ.

### A. Proposed Discovery Schedule

|   |                                | T   |
|---|--------------------------------|---|
| EVENT   | PLAINTIFFS' PROPOSAL           | NUVASIVE'S PROPOSAL                                   |
| Fact Discovery Opens  | 2/1/13 (Fed. R. Civ. P. 26(d)) | 12/16/13 (or 7 days after claim construction hearing) |
| Parties to serve initial disclosures  | 2/14/13                        | 2/14/13   |
| Parties to serve Disclosure of<br>Asserted Claims and<br>Preliminary Infringement<br>Contentions (Patent L.R. 3.1)                            | 3/7/13                         | 6/7/13  |
| Parties to serve Preliminary<br>Invalidity Contentions (Patent<br>L.R. 3.3)   | 5/6/13                         | 8/6/13  |
| Parties to exchange Preliminary<br>Claim Construction and<br>Extrinsic Evidence (Patent L.R.<br>4.1)  | 5/20/13                        | 8/20/13   |
| Parties to exchange Responsive<br>Claim Constructions (Patent<br>L.R. 4.1)  | 6/3/13                         | 9/3/13  |
| Parties to file Joint Claim<br>Construction Chart, Joint Claim<br>Construction Worksheet, and<br>Joint Hearing Statement (Patent<br>L.R. 4.2) | 6/17/13                        | 9/17/13   |
| Last day to request leave to amend/supplement pleadings   | 7/1/13                         | 8/22/14   |
| Claim construction discovery cutoff (Patent L.R. 4.3)   | 7/15/13                        | 10/15/13  |
| Opening claim construction briefs due (Patent L.R. 4.4.a)   | 7/29/13                        | 10/29/13  |

| Responsive claim construction briefs due (Patent L.R. 4.4.b)  Claim construction and tutorial hearing (Patent L.R. 2.1)  Parties to serve final infringement contentions based on claim construction order  8/12/13  11/12/13  11/12/13  12/9/13 (Patent L.R. 4.5)  230 days after claim construction order  30 days after claim construction order |          |
|---|----------|
| hearing (Patent L.R. 2.1) calendar) (Patent L.R. 2.1.a.2)  Parties to serve final infringement contentions based order order 30 days after claim construction order   |          |
| infringement contentions based order order  | truction |
| (Patent L.R. 3.6.a)   |          |
| Parties to serve final invalidity contentions based on claim construction order (Patent L.R. 3.6.b)  50 days after claim construction order order order   | ruction  |
| Parties to exchange list of expert witnesses expected to be called at trial  8/1/14 (or 3 weeks before close of fact discovery)   | e the    |
| Parties to exchange list of rebuttal expert witnesses expected to be called at trial  10/29/13  8/15/14 (or 1 week before close of fact discovery   | e the    |
| Fact discovery cut-off  11/18/13  8/22/14 (8 months after NuVasive proposes that discovery opens)   | fact     |
| Initial expert reports (by party with burden of proof on each issue)  12/16/13  9/22/14 (or 30 days after NuVasive proposes that discovery closes)  |          |
| Rebuttal expert reports 1/13/14 10/22/14 (or 30 days after opening expert reports)  | r        |
| Reply Expert Reports (for secondary considerations of non-obviousness)  1/27/14  11/5/14 (or 14 days after rebuttal expert reports)   |          |
| Expert discovery cut-off 2/24/14 12/26/14 (4 months after discovery closes)   | fact     |
| Dispositive motion cut-off 3/10/14 1/23/14 (or 30 days after discovery cut-off)   | expert   |
| Pretrial conference 4/7/14 4/6/15   |          |

No changes will be made in timing, form, or requirement for 26(a) disclosures.

## Plaintiffs' Statement Concerning Their Proposed Schedule

On August 17, 2012, Plaintiffs filed this case in the Northern District of Indiana against Defendant, NuVasive, Inc., alleging infringement of three of Plaintiffs' patents by NuVasive's manufacture and sale of certain medical devices and procedures used in spinal surgery. (Dkts. 1 & 17.) On November 8, 2012, the Northern District of Indiana granted NuVasive's motion to transfer



this case to the Southern District of California. (Dkt. 32.) With respect to the dates on which the parties differ, Plaintiffs have proposed a schedule to resolve efficiently its patent infringement claims that have been pending for nearly six months. (Dkts. 1 & 17.) Under Plaintiffs' proposed schedule, the parties would complete fact discovery by November 18, 2013 and expert discovery by February 24, 2014, and would participate in the pretrial conference on April 7, 2014. Plaintiffs' proposed schedule would allow this case to be scheduled for trial within 24 months.

In contrast, NuVasive has proposed a schedule that would be inefficient and is contrary to the Federal and Local Rules. *See* Fed. R. Civ. P. 26(d); Patent L.R. 2.5. Under NuVasive's proposal, fact discovery would not even begin until after the claim construction hearing. There is no reason why fact discovery cannot be conducted concurrently with claim construction briefing, as is typically done in patent cases and has been done in another patent case between the parties before this Court (*Warsaw Orthopedic, Inc. v. NuVasive, Inc.*, Case No. 3:08-cv-01512-CAB-MDD). Indeed, the Local Rules prohibit a party from objecting to discovery requests as premature in light of the timetable for claim construction provided by these rules except where the requests seek to elicit a party's claim construction position, a comparison of the asserted claims against the accused products or prior art, or the identification of opinions of counsel relating to allegations of willful infringement. Patent L.R. 2.5.

Furthermore, NuVasive has proposed a schedule that runs counter to the arguments it made to the Northern District of Indiana to support its transfer motion. There, NuVasive argued that trial in California would not be slower than trial in Indiana because "complex patent cases of more than two patents will be scheduled for trial within 24 months" in this district. (Dkt. 30 at 9, n. 5.) Now, however, NuVasive proposes a schedule with a trial date well beyond the two-year mark. NuVasive also proposes to extend the last day to request leave to amend or supplement the pleadings to August 22, 2014 (to coincide with its proposed close of fact discovery), presumably so that it may take discovery on an unpleaded inequitable conduct defense. Plaintiffs submit that their proposed deadline of July 1, 2013 to amend or supplement pleadings is nearly one year from the filing of the Complaint and gives sufficient time for NuVasive to conduct any necessary investigation or



discovery before amendment. NuVasive's proposal would also leave the parties with no time to take discovery on any claims or defenses raised in the amended or supplemented pleadings.

NuVasive now asserts no fewer than four separate reasons why it believes this case, which

has been pending for nearly seven months, should be further delayed: 1) the Federal Circuit has yet to rule on the appeal of the Phase I jury verdict between the parties; 2) delaying this case would supposedly promote settlement; 3) NuVasive needs more time in order to assert its own patents; and 4) bifurcating damages and willfulness would allegedly permit the parties to focus their discovery efforts. Each of these reasons fails. First, with the exception of the pending ongoing royalty issue, this Court has already decided the issues relating to liability and damages for the Phase I patents. There is no reason to assume (as NuVasive does) that the Court decided these issues incorrectly. In any event, a Federal Circuit appeal will likely be concluded before the trial in this matter, under either party's proposed schedule. Second, Plaintiffs disagree that delay would promote settlement and instead believe the opposite to be true. Third, NuVasive has had nearly seven months since this case was filed to consider asserting its own patents and has failed to identify even one that it intends to assert. Finally, bifurcation of damages and willfulness, as well as all discovery relevant to those issues, would be inefficient and burdensome given the overlap of those issues with other fact issues in this case. This would lead to duplicative fact and expert depositions, and trial testimony, and would not promote judicial economy. Accordingly, Plaintiffs propose that the Court adopt its proposed schedule as set forth above and in accordance with the Local Rules.

## NuVasive's Statement Concerning Its Proposed Schedule

The Court should stay these proceedings until the Federal Circuit has ruled on the appeal of related Case No. 08-CV-1512 ("Phase 1"). Guidance from the Federal Circuit will help define the contours of this litigation and may help the parties reach a global resolution eliminating the need for this suit altogether. In the event the Court chooses not to stay, NuVasive proposes a phased approach to litigating this case – an approach that provides the parties time to resolve their disputes informally before being compelled to engage in expensive litigation. If the parties are unable to resolve their disputes through ENE and/or mediation within 90 days, then NuVasive would assert its



1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

